Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma HELP
Based on 4,355 articles published since 2007
||||

These are the 4355 published articles about Mesothelioma that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication. 2015

Hjerpe, A / Ascoli, V / Bedrossian, C W M / Boon, M E / Creaney, J / Davidson, B / Dejmek, A / Dobra, K / Fassina, A / Field, A / Firat, P / Kamei, T / Kobayashi, T / Michael, C W / Önder, S / Segal, A / Vielh, P. ·Division of Clinical Pathology/Cytology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden. · Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy. · Rush University Medical College, Chicago, IL, USA. · Leiden Cytology and Pathology Laboratory, Lieveren, The Netherlands. · National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Perth, WA, Australia. · Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. · Department of Laboratory Medicine in Malmö, Lund University, Malmö University Hospital, Malmö, Sweden. · Department of Medicine, University of Padova, Padova, Italy. · Department of Anatomical Pathology, St Vincents Hospital, Sydney, NSW, Australia. · Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. · Division of Pathology, Yamaguchi Grand Medical Center, Hofu, Japan. · Cancer Education and Research Center, Osaka University Graduate School of Medicine, Osaka, Japan. · Department of Pathology, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, OH, USA. · Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. · Department of Tissue Pathology, PathWest Laboratory Medicine WA, QE2 Medical Centre, Perth, WA, Australia. · Department of Biopathology, Gustave Roussy Comprehensive Cancer Center, Villejuif, France. ·Cytopathology · Pubmed #26052757.

ABSTRACT: OBJECTIVE: To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. DATA SOURCES: Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. RATIONALE: This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town.

2 Guideline Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. 2015

Hjerpe, Anders / Ascoli, Valeria / Bedrossian, Carlos W M / Boon, Mathilde E / Creaney, Jenette / Davidson, Ben / Dejmek, Annika / Dobra, Katalin / Fassina, Ambrogio / Field, Andrew / Firat, Pinar / Kamei, Toshiaki / Kobayashi, Tadao / Michael, Claire W / Önder, Sevgen / Segal, Amanda / Vielh, Philippe / Anonymous6770825 / Anonymous6780825 / Anonymous6790825. ·Division of Clinical Pathology/Cytology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden. · ·Acta Cytol · Pubmed #25824655.

ABSTRACT: OBJECTIVE: To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. DATA SOURCES: Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. RATIONALE: This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town.

3 Guideline Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. 2015

Wolff, Henrik / Vehmas, Tapio / Oksa, Panu / Rantanen, Jorma / Vainio, Harri. ·Finnish Institute of Occupational Health (FIOH) Topeliuksenkatu 41aA 00250 Helsinki Finland. Henrik.Wolff@ttl.fi. · ·Scand J Work Environ Health · Pubmed #25299403.

ABSTRACT: -- No abstract --

4 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 2013

Husain, Aliya N / Colby, Thomas / Ordonez, Nelson / Krausz, Thomas / Attanoos, Richard / Beasley, Mary Beth / Borczuk, Alain C / Butnor, Kelly / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Dacic, Sanja / Fraire, Armando / Galateau-Salle, Francoise / Gibbs, Allen / Gown, Allen / Hammar, Samuel / Litzky, Leslie / Marchevsky, Alberto M / Nicholson, Andrew G / Roggli, Victor / Travis, William D / Wick, Mark / Anonymous3800735. ·Department of Pathology, University of Chicago, Chicago, IL 60637, USA. aliya.husain@uchospitals.edu · ·Arch Pathol Lab Med · Pubmed #22929121.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To provide updated practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. CONCLUSIONS: There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

5 Guideline Malignant pleural mesothelioma. 2012

Ettinger, David S / Akerley, Wallace / Borghaei, Hossein / Chang, Andrew / Cheney, Richard T / Chirieac, Lucian R / D'Amico, Thomas A / Demmy, Todd L / Ganti, Apar Kishor P / Govindan, Ramaswamy / Grannis, Frederic W / Horn, Leora / Jahan, Thierry M / Jahanzeb, Mohammad / Kessinger, Anne / Komaki, Ritsuko / Kong, Feng-Ming Spring / Kris, Mark G / Krug, Lee M / Lennes, Inga T / Loo, Billy W / Martins, Renato / O'Malley, Janis / Osarogiagbon, Raymond U / Otterson, Gregory A / Patel, Jyoti D / Schenck, Mary Pinder / Pisters, Katherine M / Reckamp, Karen / Riely, Gregory J / Rohren, Eric / Swanson, Scott J / Wood, Douglas E / Yang, Stephen C / Anonymous7940714. ·The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Baltimore, MD, USA. · ·J Natl Compr Canc Netw · Pubmed #22223867.

ABSTRACT: -- No abstract --

6 Guideline [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Pe'choux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous980676 / Anonymous990676. ·Dept of Pulmonary and Thoracic Oncology,Hospital Calmette CHRU of Lille 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr · ·Zhongguo Fei Ai Za Zhi · Pubmed #20976998.

ABSTRACT: -- No abstract --

7 Guideline Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010

Stahel, R A / Weder, W / Lievens, Y / Felip, E / Anonymous3570663. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. · ·Ann Oncol · Pubmed #20555061.

ABSTRACT: -- No abstract --

8 Guideline Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Péchoux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous2500637. ·Dept of Pulmonary and Thoracic Oncology, Hôpital Calmette, CHRU of Lille, 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr · ·Eur Respir J · Pubmed #19717482.

ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM. To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in approximately 10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.

9 Guideline Lung Cancer OncoGuia: surgical pathology report guidelines. 2009

Ramírez, Josep / Montero, M Angeles / Alejo, María / Lloreta, Josep / Anonymous691377. ·Pathology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. · ·Clin Transl Oncol · Pubmed #20045788.

ABSTRACT: -- No abstract --

10 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 2009

Husain, Aliya N / Colby, Thomas V / Ordóñez, Nelson G / Krausz, Thomas / Borczuk, Alain / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Galateau-Salle, Francoise / Gibbs, Allen R / Gown, Allen M / Hammar, Samuel P / Litzky, Leslie A / Roggli, Victor L / Travis, William D / Wick, Mark R. ·Department of Pathology, University of Chicago, Chicago, IL 60631, USA. ahusain@bsd.uchicago.edu · ·Arch Pathol Lab Med · Pubmed #19653732.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To develop practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

11 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008

Stahel, R A / Weder, W / Felip, E / Anonymous3990598. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. · ·Ann Oncol · Pubmed #18456764.

ABSTRACT: -- No abstract --

12 Guideline Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. 2007

Marchevsky, Alberto M / Wick, Mark R. ·Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. marchevsky@cshs.org · ·Appl Immunohistochem Mol Morphol · Pubmed #17525624.

ABSTRACT: There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for their individual practices. In contrast, other medical specialties have crafted many evidence-based practice guidelines (EBG) that are widely used; these have helped to augment standardization and cost effectiveness. In particular, the use of several "epithelial" and "mesothelial" antibodies has been proposed to distinguish epithelioid malignant mesothelioma from metastatic pulmonary adenocarcinoma. Other authors have previously done systematic literature reviews of this subject up through 2004 and integrated the results of 88 publications into summarized test-performance values for 15 preselected immunohistochemical markers. The results suggested that 7 tests provide optimal sensitivity and specificity (MOC-31, BG8, CEA, TTF-1, CK5/6, WT-1, and HBME-1), but they provide no guidance for integration of such data into EBG. Odds ratios (ORs) were employed to compare the effectiveness of any single test, and chosen combinations thereof, in the differential diagnosis of malignant mesothelioma and metastatic pulmonary adenocarcinoma. Surprisingly, selected single immunostains or antibody pairs yielded ORs (varying from 96.34 to 1233.19) that were equal or better in efficacy when compared with more comprehensive panels. These results support the potential value of systematic reviews, meta-analysis, and OR calculations for development of EBG in diagnostic immunohistology.

13 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007

Anonymous5730567 / Manegold, C. · ·Ann Oncol · Pubmed #17491037.

ABSTRACT: -- No abstract --

14 Guideline Recommendations for the reporting of pleural mesothelioma. 2007

Butnor, Kelly J / Sporn, Thomas A / Ordonez, Nelson G / Anonymous2130561. ·Department of Pathology, University of Vermont, 111 Colchester Avenue, Burlington, VT 05401, USA. kelly.butnor@vtmednet.org · ·Hum Pathol · Pubmed #17276491.

ABSTRACT: It has been evident for decades that pathology reports are very variable even within a single institution. Standardization of reporting is the optimal way to ensure that information necessary for patient management, prognostic and predictive factor assessment, grading, staging, analysis of outcomes, and tumor registries is included in pathology reports. In recent years, 2 societies (first the Association of Directors of Anatomic and Surgical Pathology [ADASP] and then the College of American Pathologists [CAP]) have undertaken to publish guidelines for the reporting of common cancers. The CAP assigned multidisciplinary groups of pathologists, surgeons, radiation, and medical oncologists to develop the protocols. Other pathologists and clinicians then reviewed them. After those reviews the protocols were reviewed by multiple CAP committees and finally approved by the Board of Governors. The ADASP, in contrast, chose a pathologist expert in each filed to assemble a group from within the pathology community (with clinician input if desired) to write specific cancer protocols. These were then approved by the ADASP council and subsequently by the membership. Although both societies began the process at approximately the same time, the streamlined approach adopted by the ADASP enabled them to publish years earlier in pathology journals frequented by anatomic pathologists. Although the formats are somewhat different, the contents are essentially the same. The American College of Surgery Commission on Cancer (COC) accredits cancer centers in the United States. Recently, the COC decided to require elements, deemed as essential by the CAP, to be described in all pathology reports in their accredited cancer centers as of January 2004. Importantly, they do not require that the specific CAP protocols or synoptic reports be used. The ADASP has updated all of its protocols to comply with the COC requirements in the form of 37 uniform checklists. The checklists use the staging criteria sited in the American Joint Committee on Cancer 2002 Staging Manual (sixth edition) but include a variety of other references listed in each of the checklists. Moreover, the checklists are formatted for ease of use. They may be used as templates for uniform reporting and are designed to be compatible with voice-activated transcription. The different elements in these revised ADASP diagnostic checklists have been divided into required and optional. The term required in this context only signifies compliance with the COC guidelines. The ADASP realizes that specimens and practices vary, and it will not be possible to report these elements in every case. However, the ADASP hopes that pathologists will find these checklists to be useful in daily clinical practice, while facilitating compliance with the new COC requirements.

15 Editorial Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. 2017

Ban, Cheng-Jun / Shi, Huan-Zhong / Zhang, Yu-Hui. ·Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020; Beijing Institute of Respiratory Medicine, Beijing 100020, China. ·Chin Med J (Engl) · Pubmed #28051015.

ABSTRACT: -- No abstract --

16 Editorial [Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough]. 2016

Brosseau, S / Naltet, C / Gounant, V / Zalcman, G. ·Service d'oncologie thoracique, CIC 1425-CLIP(2) Paris-Nord, AP-HP, hôpital Bichat-Claude-Bernard, université Paris-Diderot, 46, rue Henri-Huchard, 75018 Paris, France. · Service d'oncologie thoracique, CIC 1425-CLIP(2) Paris-Nord, AP-HP, hôpital Bichat-Claude-Bernard, université Paris-Diderot, 46, rue Henri-Huchard, 75018 Paris, France; U830 Inserm « Génétique et biologie des cancers », centre de recherche, institut Curie, 26, rue d'Ulm, 75248 Paris cedex 05, France. Electronic address: gerard.zalcman@aphp.fr. ·Rev Mal Respir · Pubmed #27968925.

ABSTRACT: -- No abstract --

17 Editorial Malignant pleural mesothelioma. 2016

Klepetko, Walter. ·Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria. thoracicsurgery@meduniwien.ac.at. ·Wien Klin Wochenschr · Pubmed #27457871.

ABSTRACT: -- No abstract --

18 Editorial The staging of malignant pleural mesothelioma: are we any nearer to squaring the circle? 2016

Waller, David A. ·Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK david.waller@uhl-tr.nhs.uk. ·Eur J Cardiothorac Surg · Pubmed #26802144.

ABSTRACT: -- No abstract --

19 Editorial The mesothelioma surgery shift. 2016

Flores, Raja M. ·Department of Thoracic Surgery, Icahn School of Medicine, Mount Sinai Health System, New York, NY. Electronic address: raja.flores@mountsinai.org. ·J Thorac Cardiovasc Surg · Pubmed #26621318.

ABSTRACT: -- No abstract --

20 Editorial Pleurectomy decortication for mesothelioma: The procedure of choice when possible. 2016

Flores, Raja M. ·Department of Thoracic Surgery, Icahn School of Medicine, Mount Sinai Health System, New York, NY. Electronic address: raja.flores@mountsinai.org. ·J Thorac Cardiovasc Surg · Pubmed #26611749.

ABSTRACT: -- No abstract --

21 Editorial SMART or simply bold? 2016

Rusch, Valerie W / Rimner, Andreas / Adusumilli, Prasad S. ·Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: ruschv@mskcc.org. · Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. · Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY. ·J Thorac Cardiovasc Surg · Pubmed #26586361.

ABSTRACT: -- No abstract --

22 Editorial What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice. 2016

Treasure, Tom. ·Clinical Operational Research Unit, University College London, London, United Kingdom. Electronic address: tom.treasure@gmail.com. ·J Thorac Cardiovasc Surg · Pubmed #26519246.

ABSTRACT: -- No abstract --

23 Editorial The Second Mediterranean Symposium: considering mesothelioma from a local and international perspective. 2015

Treasure, Tom. ·Professor of Cardiothoracic Surgery, Clinical Operational Research Unit, University College London, London, UK. ·Future Oncol · Pubmed #26638914.

ABSTRACT: -- No abstract --

24 Editorial 50th Anniversary Perspective on Volume 1: Urschel HC, Paulson DL. Mesotheliomas of the Pleura. Ann Thorac Surg 1965;1:559-73. 2015

Rusch, Valerie W. ·Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: ruschv@mskcc.org. ·Ann Thorac Surg · Pubmed #26434424.

ABSTRACT: -- No abstract --

25 Editorial [III Italian Consensus Conference on pleural mesothelioma]. 2015

Zocchetti, Carlo. ·. carlo.zocchetti@libero.it. ·Med Lav · Pubmed #26384257.

ABSTRACT: -- No abstract --

Next